Profusa, Inc. (NASDAQ:PFSA – Get Free Report) was the recipient of a large decline in short interest in the month of July. As of July 15th, there was short interest totaling 53,192 shares, a decline of 77.4% from the June 30th total of 234,995 shares. Approximately 28.8% of the company’s shares are sold short. Based on an average daily trading volume, of 282,122 shares, the short-interest ratio is presently 0.2 days.
Profusa Stock Performance
Shares of Profusa stock traded down $0.49 during trading on Monday, hitting $1.22. 7,930,014 shares of the stock traded hands, compared to its average volume of 218,844. The stock has a market cap of $231,800.00, a P/E ratio of -0.00 and a beta of 0.46. The company has a fifty day moving average price of $4.93 and a two-hundred day moving average price of $42.05. Profusa has a twelve month low of $0.94 and a twelve month high of $4,162.50.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the company. Wall Street Zen raised Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.
About Profusa
Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.
The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.
See Also
- Five stocks we like better than Profusa
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.
